BR112015022141A2 - Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrna - Google Patents
Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrnaInfo
- Publication number
- BR112015022141A2 BR112015022141A2 BR112015022141A BR112015022141A BR112015022141A2 BR 112015022141 A2 BR112015022141 A2 BR 112015022141A2 BR 112015022141 A BR112015022141 A BR 112015022141A BR 112015022141 A BR112015022141 A BR 112015022141A BR 112015022141 A2 BR112015022141 A2 BR 112015022141A2
- Authority
- BR
- Brazil
- Prior art keywords
- mrna
- capping
- efficiency
- capding
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
MÉTODO DE QUANTIFICAÇÃO DE EFICIÊNCIA DE CAPEAMENTO DE MRNA, KIT E MÉTODO DE FABRICAÇÃO DE MRNA. A presente invenção proporciona, entre outras coisas, métodos de quantificação de eficiência de capeamento de mRNA, particularmente mRNA sintetizado in vitro. Em algumas modalidades, métodos de acordo com a presente invenção compreendem proporcionar uma amostra de mRNA contendo mRNA capeado e não capeado, proporcionando uma substância de ligação específica de capeamento, sob condições que permitem a formação de um complexo entre a substância de ligação específica de capeamento e o mRNA capeado, e determinação quantitativa da quantidade do complexo em comparação com um controle, quantificando desse modo a eficiência de capeamento de mRNA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784253P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027602 WO2014152673A1 (en) | 2013-03-14 | 2014-03-14 | Quantitative assessment for cap efficiency of messenger rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015022141A2 true BR112015022141A2 (pt) | 2017-08-29 |
Family
ID=50625146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022141A BR112015022141A2 (pt) | 2013-03-14 | 2014-03-14 | Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrna |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10626439B2 (pt) |
| EP (2) | EP2971098B1 (pt) |
| JP (1) | JP2016515216A (pt) |
| CN (1) | CN105209633A (pt) |
| AU (1) | AU2014239264A1 (pt) |
| BR (1) | BR112015022141A2 (pt) |
| CA (1) | CA2903488A1 (pt) |
| DK (1) | DK2971098T3 (pt) |
| EA (1) | EA201591286A1 (pt) |
| ES (1) | ES2708562T3 (pt) |
| MX (1) | MX2015011945A (pt) |
| TR (1) | TR201901396T4 (pt) |
| WO (1) | WO2014152673A1 (pt) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| CN111671918A (zh) | 2011-06-08 | 2020-09-18 | 川斯勒佰尔公司 | Mrna递送的脂质纳米颗粒组合物和方法 |
| EP3336082B1 (en) | 2011-06-08 | 2020-04-15 | Translate Bio, Inc. | Cleavable lipids |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| AU2014236305B2 (en) | 2013-03-14 | 2019-01-17 | Ethris Gmbh | CFTR mRNA compositions and related methods and uses |
| ES2708561T3 (es) | 2013-03-14 | 2019-04-10 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| EP2971098B1 (en) | 2013-03-14 | 2018-11-21 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| JP2016514970A (ja) | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのキャップ効率の定量的評価 |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| CN106413811A (zh) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | 精氨基琥珀酸合成酶缺乏症的mrna疗法 |
| ES2750661T3 (es) | 2014-04-25 | 2020-03-26 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| SE539096C2 (en) * | 2015-03-18 | 2017-04-04 | C Conjunction Ab | A method, system and software application for providing context based commercial information |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| AU2016324463B2 (en) | 2015-09-17 | 2022-10-27 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| HUE064227T2 (hu) | 2015-09-21 | 2024-02-28 | Trilink Biotechnologies Llc | Módszer 5'-sapkával ellátott rns-ek szintetizálására |
| US10144942B2 (en) | 2015-10-14 | 2018-12-04 | Translate Bio, Inc. | Modification of RNA-related enzymes for enhanced production |
| AU2016340183A1 (en) * | 2015-10-16 | 2018-04-19 | Modernatx, Inc. | mRNA cap analogs and methods of mRNA capping |
| US11866754B2 (en) * | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| US20210108252A1 (en) * | 2015-12-09 | 2021-04-15 | Novartis Ag | Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry |
| US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3442590A2 (en) | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| HRP20230050T1 (hr) | 2016-05-18 | 2023-03-03 | Modernatx, Inc. | Polinukleotidi koji kodiraju interleukin-12 (il12) i njihova upotreba |
| GB201615233D0 (en) * | 2016-09-08 | 2016-10-26 | Bbi Solutions Oem Ltd | Solid Phase Conjugate |
| DK3585892T3 (da) | 2017-02-27 | 2022-08-22 | Translate Bio Inc | Fremgangsmåder til oprensning af messenger-rna |
| WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
| IL268857B2 (en) | 2017-02-27 | 2024-09-01 | Translate Bio Inc | Methods for the purification of messenger RNA |
| EP3624824B1 (en) | 2017-05-16 | 2024-07-10 | Translate Bio, Inc. | Codon-optimized mrna encoding cftr for use in treating cystic fibrosis |
| WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
| EP3645711A4 (en) * | 2017-06-30 | 2021-04-21 | Codexis, Inc. | T7 RNA POLYMERASE VARIANTS |
| CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| EP3861108A1 (en) | 2018-10-04 | 2021-08-11 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
| US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
| MX2021003772A (es) * | 2018-10-26 | 2021-05-27 | Illumina Inc | Modulacion de globulos de polimero para procesamiento de adn. |
| EP3877538A1 (en) | 2018-11-08 | 2021-09-15 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| US20220040281A1 (en) | 2018-12-21 | 2022-02-10 | Curevac Ag | Rna for malaria vaccines |
| KR20220029556A (ko) | 2019-05-15 | 2022-03-08 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| JP2022544412A (ja) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| CN112626177A (zh) * | 2019-10-09 | 2021-04-09 | 华中科技大学 | 一种快速定量检测rna加帽效率的方法 |
| AU2021216658A1 (en) | 2020-02-04 | 2022-06-23 | CureVac SE | Coronavirus vaccine |
| CA3170740A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| BR112022026469A2 (pt) * | 2020-06-26 | 2023-03-07 | Carisma Therapeutics Inc | Transfecção de mrna de células imunes |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| CN113308504A (zh) * | 2020-08-20 | 2021-08-27 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5`帽子类似物及其制备方法和应用 |
| EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| WO2022200575A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
| EP4351777A1 (en) * | 2021-06-07 | 2024-04-17 | The University of Massachusetts | Apparatus and method for continuous production of rna |
| WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| CN115260264B (zh) * | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| AU2022430003B9 (en) | 2022-02-28 | 2023-11-23 | Guangzhou Henovcom Bioscience Co., Ltd. | Compounds for rna capping and uses thereof |
| JP2024522732A (ja) * | 2022-04-15 | 2024-06-21 | サーモ フィニガン リミテッド ライアビリティ カンパニー | Ｍｒｎａキャッピング効率の定量的モニタリング方法 |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024161314A1 (en) * | 2023-01-31 | 2024-08-08 | Seqirus Inc. | Capping assay |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| CN116640833A (zh) * | 2023-06-01 | 2023-08-25 | 中国医学科学院医学生物学研究所 | 一种利用毛细管电泳技术自动化批量检测mRNA加帽率的方法 |
| CN116426610B (zh) * | 2023-06-08 | 2024-01-05 | 启辰生生物科技(珠海)有限公司 | 一种LC-MS法准确定量mRNA加帽效率的方法 |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3529478A1 (de) | 1985-08-16 | 1987-02-19 | Boehringer Mannheim Gmbh | 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| EP0463109A4 (en) | 1989-03-24 | 1992-11-19 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| US5356804A (en) | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| DE4140463A1 (de) | 1991-12-09 | 1993-06-17 | Boehringer Mannheim Gmbh | 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben |
| US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| ATE232880T1 (de) | 1996-11-18 | 2003-03-15 | Takeshi Imanishi | Neue nucleotidanaloga |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6143877A (en) | 1997-04-30 | 2000-11-07 | Epoch Pharmaceuticals, Inc. | Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids |
| EP2341058A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
| US6127121A (en) | 1998-04-03 | 2000-10-03 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination |
| CA2384407C (en) | 1999-08-30 | 2009-10-20 | Roche Diagnostics Gmbh | 2-azapurine compounds and their use |
| US6660845B1 (en) | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| US20020197622A1 (en) | 2001-01-31 | 2002-12-26 | Mcdevitt John T. | Method and apparatus for the confinement of materials in a micromachined chemical sensor array |
| WO2004020575A2 (en) * | 2002-06-24 | 2004-03-11 | Exiqon A/S | Methods and systems for detection and isolation of a nucleotide sequence |
| AU2007238624B2 (en) | 2006-04-14 | 2012-05-31 | Cellscript, Llc | Kits and methods for generating 5' capped RNA |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US20100035249A1 (en) * | 2008-08-05 | 2010-02-11 | Kabushiki Kaisha Dnaform | Rna sequencing and analysis using solid support |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| JP2016514970A (ja) | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのキャップ効率の定量的評価 |
| EP2971098B1 (en) | 2013-03-14 | 2018-11-21 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
| MX2020011167A (es) | 2018-04-25 | 2021-02-09 | Ethris Gmbh | Formulaciones a base de lipidos para el suministro de arn. |
-
2014
- 2014-03-14 EP EP14720376.4A patent/EP2971098B1/en active Active
- 2014-03-14 CA CA2903488A patent/CA2903488A1/en not_active Abandoned
- 2014-03-14 TR TR2019/01396T patent/TR201901396T4/tr unknown
- 2014-03-14 ES ES14720376T patent/ES2708562T3/es active Active
- 2014-03-14 DK DK14720376.4T patent/DK2971098T3/en active
- 2014-03-14 MX MX2015011945A patent/MX2015011945A/es unknown
- 2014-03-14 EA EA201591286A patent/EA201591286A1/ru unknown
- 2014-03-14 WO PCT/US2014/027602 patent/WO2014152673A1/en active Application Filing
- 2014-03-14 AU AU2014239264A patent/AU2014239264A1/en not_active Withdrawn
- 2014-03-14 US US14/775,844 patent/US10626439B2/en active Active
- 2014-03-14 JP JP2016502491A patent/JP2016515216A/ja not_active Withdrawn
- 2014-03-14 EP EP18207398.1A patent/EP3495505B1/en active Active
- 2014-03-14 CN CN201480010108.7A patent/CN105209633A/zh active Pending
- 2014-03-14 BR BR112015022141A patent/BR112015022141A2/pt not_active IP Right Cessation
-
2020
- 2020-01-16 US US16/744,985 patent/US11104934B2/en active Active
-
2021
- 2021-05-19 US US17/325,092 patent/US11920182B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3495505A1 (en) | 2019-06-12 |
| ES2708562T3 (es) | 2019-04-10 |
| CN105209633A (zh) | 2015-12-30 |
| EA201591286A1 (ru) | 2016-02-29 |
| AU2014239264A1 (en) | 2015-08-27 |
| TR201901396T4 (tr) | 2019-02-21 |
| US11920182B2 (en) | 2024-03-05 |
| JP2016515216A (ja) | 2016-05-26 |
| WO2014152673A1 (en) | 2014-09-25 |
| US20210371900A1 (en) | 2021-12-02 |
| US20200318156A1 (en) | 2020-10-08 |
| US11104934B2 (en) | 2021-08-31 |
| CA2903488A1 (en) | 2014-09-25 |
| US20160002705A1 (en) | 2016-01-07 |
| EP2971098B1 (en) | 2018-11-21 |
| DK2971098T3 (en) | 2019-02-18 |
| MX2015011945A (es) | 2015-12-01 |
| EP3495505B1 (en) | 2024-09-11 |
| US10626439B2 (en) | 2020-04-21 |
| EP2971098A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022141A2 (pt) | Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrna | |
| BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
| BR112014010955A2 (pt) | sistema e método para processar amostras | |
| BR112016024072A2 (pt) | métodos, kits e aparelho para ampliar uma população de células | |
| MX2015011944A (es) | Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. | |
| BR112014030298A2 (pt) | ensaios multiplexados baseados em aptâmero | |
| BR112016010510A2 (pt) | método, arranjo e uso do mesmo | |
| BR112016023417A2 (pt) | predição in vitro de meia-vida in vivo | |
| BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
| BRPI1012526B8 (pt) | uso de axl como um biomarcador para a detecção da ocorrência de transição epitélio-mesenquimal (tem), métodos para detecção da ocorrência de tem, para identificação de um agente capaz de inibir ou reverter tem e uso de um kit | |
| BR112015017354A2 (pt) | método para detectar pelo menos uma base modificada | |
| BR112019003361A2 (pt) | métodos e usos de frações de material orgânico dissolvido para ligação a íons metálicos | |
| MX2015013310A (es) | Metodo y reactivo para determinar metabolitos de la vitamina d. | |
| BR112017010069A2 (pt) | redução seletiva de resíduos cisteína em anticorpos para il-17 | |
| BR112014026568A2 (pt) | método e aparelho para projeto de componentes de oleoduto | |
| BR112016006637A2 (pt) | método para introduzir uma substância em uma planta, e, planta | |
| BR112016001461A2 (pt) | Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína | |
| BR112018015965A2 (pt) | método para determinação de helicobacter pylori | |
| BR112013007871A2 (pt) | quantificação e caracterização de alérgenos | |
| BR112017003167A2 (pt) | método in vitro e aparelho para análise do comportamento de substâncias em ambiente fisiológico simulado | |
| MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
| BR112015010399A2 (pt) | método e kit para a determinação de cobre livre no soro | |
| BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
| WO2012145516A3 (en) | Methods and kits for quantitative determination of total organic acid content in a coolant | |
| BR112016000231A8 (pt) | métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |